SCHEMBL6530604

SCHEMBL6530604

CCc1ccc(-n2cc(CO)cn2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.41
TP53 P04637 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 2/20 0.41
MAPT P10636 2/20 0.41
HPGD P15428 2/20 0.41
ALOX15 P16050 1/20 0.41
ALOX12 P18054 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
DRD4 P21917 5/20 0.40
DRD2 P14416 3/20 0.40
HTR2C P28335 2/20 0.38
ADORA3 P0DMS8 1/20 0.38
DRD3 P35462 2/20 0.38
KCNH2 Q12809 1/20 0.38
APOBEC3G Q9HC16 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6533713 0.84 NOTUM (0.51) SMN1; SMN2MEN1KMT2AKDM4EALDH1A1
SCHEMBL1930732 0.83 GABRA1 (0.43) LMNAMEN1KMT2AKDM4EALDH1A1
SCHEMBL12194623 0.82 ACACB (0.39) LMNAMEN1KMT2ADRD4DRD2
SCHEMBL15180418 0.81 DRD4 (0.52) LMNAMEN1KMT2AKDM4EALDH1A1
SCHEMBL6533912 0.81 DRD4 (0.55) LMNAKDM4EMAPTMAPK1DRD4
SCHEMBL28980400 0.81 MEN1 (0.41) LMNAMEN1KMT2AKDM4EALDH1A1
SCHEMBL2412911 0.80 GAA (0.58) LMNATP53SMN1; SMN2MEN1KMT2A
SCHEMBL6532804 0.80 NPBWR1 (0.43) DRD4DRD2HTR2CDRD3KCNH2
SCHEMBL16062853 0.79 RXRA (0.47) LMNATP53SMN1; SMN2MEN1KMT2A
SCHEMBL3113800 0.78 MELK (0.58)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8759366-B2 Aminopyrimidines as SYK inhibitors MERCK SHARP & DOHME CORP. (US) 2014-06-24 US disclosed
US-8551984-B2 Aminopyrimidines as SYK inhibitors MERCK SHARP & DOHME CORP. (US) 2013-10-08 US disclosed
US-20120277192-A1 AMINOPYRIMIDINES AS SYK INHIBITORS MERCK SHARP & DOHME LLC 2012-11-01 US disclosed
WO-2005040127-A1 NOVEL COMPOUNDS AS AGONIST FOR PPAR GAMMA AND PPAR ALPHA, METHOD FOR PREPARATION OF THE SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME LG LIFE SCIENCES LTD. (KR) 2005-05-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120277192-A1 AMINOPYRIMIDINES AS SYK INHIBITORS SYK, BTK, LCK LMNA 4848/4885TP53 1516/4885SMN1; SMN2 4226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.